ZENTIVA S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.38 RON | +1.20% |
|
+6.29% | +15.75% |
| Sales 2022 | 760M 164M 13.68B | Sales 2023 | 954M 206M 17.18B | Capitalization | 2.04B 440M 36.66B |
|---|---|---|---|---|---|
| Net income 2022 | 99M 21.39M 1.78B | Net income 2023 | 193M 41.69M 3.48B | EV / Sales 2022 | 1.79 x |
| Net Debt 2022 | 7.62M 1.65M 137M | Net cash position 2023 | 6.15M 1.33M 111M | EV / Sales 2023 | 2.13 x |
| P/E ratio 2022 |
13.6
x | P/E ratio 2023 |
10.6
x | Employees | 952 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 4.05% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.20% | ||
| 1 week | +6.29% | ||
| Current month | +13.42% | ||
| 1 month | +11.92% | ||
| 3 months | +16.55% | ||
| 6 months | +48.25% | ||
| Current year | +15.75% |
1 week
3.18
3.38
1 month
2.903.38
Current year
2.783.38
1 year
1.793.38
3 years
1.703.38
5 years
1.705.34
10 years
1.105.34
| Managers | Title | Age | Since |
|---|---|---|---|
Simona Cocos
CEO | Chief Executive Officer | 57 | 01/09/01 |
Daniel Nitulescu
DFI | Director of Finance/CFO | - | - |
Margareta Tanase
BRD | Director/Board Member | 64 | 01/00/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Simona Cocos
CEO | Chief Executive Officer | 57 | 01/09/01 |
Margareta Tanase
BRD | Director/Board Member | 64 | 01/00/01 |
| Director/Board Member | 53 | 20/17/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 3.38 | +1.20% | 1,555 |
| 25/24/25 | 3.34 | 0.00% | 9 |
| 24/24/24 | 3.34 | +1.83% | 6,221 |
| 23/24/23 | 3.28 | 0.00% | 1,730 |
| 22/24/22 | 3.28 | +3.14% | 14,054 |
End-of-day quote Bucharest S.E., April 26, 2024
More quotes
Zentiva SA is a Romania-based company engaged in the pharmaceutical industry. The Company is primarily engaged in the production and commercialization of pharmaceutical preparations. The Companyâs portfolio includes approximately 280 products and drugs for cardiovascular, nervous and digestive systems; pain treatment, and urological and anti-inflammatory diseases, among others. Additionally, the Company is active in the production of dietary supplements and vitamins. It has production sites in Czech Republic, Slovakia, Romania and Turkey. As of December 31, 2011, Venoma Holdings Limited held a 50.98% stake in Zentiva SA. The Company had one wholly owned subsidiary, Pallady Business Park SRL, as of December 31, 2011.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +15.75% | 505M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- SCD Stock
